Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:DMACNASDAQ:FBRXNYSE:IKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$1.57-3.7%$1.82$1.43▼$4.98$157.64M1.62195,548 shs176,049 shsDMACDiaMedica Therapeutics$3.98+3.9%$4.22$2.14▼$6.82$170.57M1.2977,191 shs108,247 shsFBRXForte Biosciences$6.80+8.3%$6.61$4.11▼$28.68$44.76M2.82153,319 shs6,559 shsIKTInhibikase Therapeutics$2.23+1.8%$2.10$1.12▼$4.20$165.78M1.01233,912 shs154,756 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-2.40%-4.68%+4.49%-35.83%-29.44%DMACDiaMedica Therapeutics+1.86%-4.25%+10.37%-39.01%+22.76%FBRXForte Biosciences-1.57%-5.71%+19.62%-43.47%+20,973.83%IKTInhibikase Therapeutics+9.50%+4.78%+5.80%-6.41%+67.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.7679 of 5 stars3.53.00.00.02.90.81.3DMACDiaMedica Therapeutics1.4885 of 5 stars3.52.00.00.02.60.00.0FBRXForte Biosciences2.9873 of 5 stars3.53.00.00.02.71.71.3IKTInhibikase Therapeutics1.3755 of 5 stars3.30.00.00.02.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$10.00536.94% UpsideDMACDiaMedica Therapeutics 3.00Buy$8.00101.01% UpsideFBRXForte Biosciences 3.00Buy$32.50377.94% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50191.48% UpsideCurrent Analyst Ratings BreakdownLatest FBRX, DMAC, ACIU, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.004/3/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $61.003/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/19/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/14/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$28.30M5.57N/AN/A$2.12 per share0.74DMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$24.30 per shareN/AIKTInhibikase Therapeutics$260K637.63N/AN/A$1.78 per share1.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%N/ADMACDiaMedica Therapeutics-$19.38M-$0.60N/AN/AN/AN/A-43.67%-40.81%5/13/2025 (Confirmed)FBRXForte Biosciences-$31.48M-$16.29N/AN/AN/AN/A-151.43%-118.92%N/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/ALatest FBRX, DMAC, ACIU, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million3/17/2025Q4 2024DMACDiaMedica Therapeutics-$0.17-$0.18-$0.01-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.861.86DMACDiaMedica TherapeuticsN/A11.8111.81FBRXForte BiosciencesN/A2.062.06IKTInhibikase TherapeuticsN/A0.850.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%DMACDiaMedica Therapeutics10.12%FBRXForte Biosciences77.63%IKTInhibikase Therapeutics3.81%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%DMACDiaMedica Therapeutics7.30%FBRXForte Biosciences3.10%IKTInhibikase Therapeutics4.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million94.39 millionOptionableDMACDiaMedica Therapeutics2042.86 million39.68 millionOptionableFBRXForte Biosciences56.58 million6.20 millionOptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableFBRX, DMAC, ACIU, and IKT HeadlinesRecent News About These CompaniesFormer Inhibikase leader launches new biotech for midstage Parkinson’s assetMay 12 at 10:00 PM | fiercebiotech.comFairmount Funds Management LLC Purchases Shares of 6,125,000 Inhibikase Therapeutics, Inc. (NYSE:IKT)May 10 at 8:05 AM | marketbeat.comWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Up 6.22%May 9, 2025 | aaii.comBlackstone Inc. Makes New Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)May 8, 2025 | marketbeat.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)May 5, 2025 | prnewswire.comGeode Capital Management LLC Purchases 272,813 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT)May 3, 2025 | marketbeat.comInhibikase Therapeutics: A Hold With Uncertain Prospects In PAHMay 2, 2025 | seekingalpha.comNantahala Capital Management LLC Makes New $7.12 Million Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)April 30, 2025 | marketbeat.comWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 5.30%April 17, 2025 | aaii.comInhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-marketApril 16, 2025 | nasdaq.comInhibikase Therapeutics Advances PAH Treatment with New LeadershipApril 14, 2025 | tipranks.comInhibikase Therapeutics announces appointment of McIntyre as CFOApril 14, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial OfficerApril 14, 2025 | globenewswire.comWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 14.13%April 8, 2025 | aaii.comHedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term lossesApril 4, 2025 | finance.yahoo.comInhibikase Therapeutics (IKT) Receives a Hold from H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent ActivityMarch 27, 2025 | globenewswire.comInhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowMarch 5, 2025 | zacks.comInhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSOFebruary 24, 2025 | markets.businessinsider.comInhibikase Announces Expansion of Senior Leadership TeamFebruary 24, 2025 | globenewswire.comInhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthFebruary 18, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBRX, DMAC, ACIU, and IKT Company DescriptionsAC Immune NASDAQ:ACIU$1.57 -0.06 (-3.68%) As of 04:00 PM EasternAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.DiaMedica Therapeutics NASDAQ:DMAC$3.98 +0.15 (+3.92%) As of 04:00 PM EasternDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Forte Biosciences NASDAQ:FBRX$6.80 +0.52 (+8.28%) As of 03:58 PM EasternForte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Inhibikase Therapeutics NYSE:IKT$2.23 +0.04 (+1.83%) As of 04:00 PM EasternInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
